CaSfA - Cancer Support for All
News from CaSfA's Director

prostate cancer

USPSTF's Recommendations for PSA Testing

The US Preventive Services Task Force recently released a draft statement with updated advice for the use of Prostate Specific Antigen (PSA) in screening for prostate cancer.  They will be accepting public feedback regarding their recommendations until May 8, 2017, after which time a final recommendation will be released.
Back in 2012, the USPSTF unequivocally told doctors to discourage patients from getting PSA testing.  They stated that the risks of false positives and overtreatment outweighed the benefits.

Treatment Options in Early Prostate Cancer

An important study looking at the treatment of early stage prostate cancer was published in the New England Journal of Medicine on Wednesday (   The use of prostate-specific antigen (PSA) testing has dramatically increased the diagnosis of prostate cancer.  Close to 181,000 cases of prostate cancer will be diagnosed in the US in 2016 and over 26,000 men will die of the disease.  But many cases of this cancer will progress slowly and not lead to death.

16th Annual Prostate Cancer Symposium

I attended the Annual Massachusetts Prostate Cancer Symposium on Friday, May 17.  I listened to some great lectures.  Especially interesting were the talks about PSA (prostate-specific antigen) testing.  This blood test started being used in the mid 1990's.  Since it's use began, we have seen a doubling in the rate of prostate cancer, but not much change in the number of men dying from the disease.

Many have taken a closer look at the PSA screening test and prostate cancer as a whole.
Website Builder provided by  Vistaprint